Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$48.98 USD

48.98
1,184,593

+2.27 (4.86%)

Updated May 31, 2024 04:00 PM ET

After-Market: $49.03 +0.05 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nalak Das headshot

5 Stocks With Recent Price Strength to Gain From July Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, FC, ASC, SNEX and ARLP.

Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 29%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 29.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Has McKesson (MCK) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how McKesson (MCK) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

Best Momentum Stocks to Buy for July 12th

by Zacks Equity Research

CCBG, IMCR and FSTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2022.

Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program

by Zacks Equity Research

Vertex (VRTX) will acquire ViaCyte for $320 million in cash.

Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts See a 36% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 35.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are Medical Stocks Lagging Galapagos (GLPG) This Year?

by Zacks Equity Research

Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

Zacks.com featured highlights include Immunocore Holdings, United Fire Group, FTI Consulting, Consolidated Water and Huron Consulting

by Zacks Equity Research

Immunocore Holdings, United Fire Group, FTI Consulting, Consolidated Water and Huron Consulting are part of zacks Screen of the week article.

Here's What Could Help Immunocore Holdings PLC Sponsored ADR (IMCR) Maintain Its Recent Price Strength

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Nalak Das headshot

5 Stocks With Recent Price Strength to Maximize Your Gains

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, UFCS, CWCO, HURN and FCN.

Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?

by Zacks Equity Research

Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health

by Zacks Equity Research

Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

by Zacks Equity Research

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.

Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study

by Zacks Equity Research

Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.